Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Charles E. Geyer"'
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Rare subtypes of triple-negative breast cancers (TNBC) are a heterogenous group of tumors, comprising 5–10% of all TNBCs. Despite accounting for an absolute number of cases in aggregate approaching that of other less common, but well studi
Externí odkaz:
https://doaj.org/article/4e4b7df9a81044c7a074d3e2ffbe07ea
Autor:
Pooja P. Advani, Kathryn J. Ruddy, Joerg Herrmann, Jordan C. Ray, Emily C. Craver, Greg Yothers, Reena S. Cecchini, Corey Lipchik, Huichen Feng, Priya Rastogi, Eleftherios P. Mamounas, Sandra M. Swain, Charles E. Geyer, Norman Wolmark, Soonmyung Paik, Katherine L. Pogue-Geile, Gerardo Colon-Otero, Edith A. Perez, Nadine Norton
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe cardiotoxic effects of doxorubicin, trastuzumab, and other anticancer agents are well known, but molecular genetic testing is lacking for the early identification of patients at risk for therapy-related cardiac toxicity.MethodsUsing the
Externí odkaz:
https://doaj.org/article/0bd121bdd57c4d5fb05b24d6e6c5fc77
Autor:
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated
Externí odkaz:
https://doaj.org/article/c268c669d03547e1b3867ec85f83f413
Autor:
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort st
Externí odkaz:
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Autor:
Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John P. Crown, Michael P. Thirlwell, David M. Ellison, Jean-Francois Boileau, Patrick J. Flynn, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported men
Externí odkaz:
https://doaj.org/article/2fe38dd1eb3c43a496b8bd443b9c9acc
Autor:
Priya Rastogi, Gong Tang, Saima Hassan, Charles E. Geyer, Catherine A. Azar, Gustav C. Magrinat, J. Marie Suga, Harry D. Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Francois Boileau, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark
Publikováno v:
Breast Cancer Research and Treatment. 199:243-252
Autor:
Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios (Terry) Mamounas, Charles E. Geyer Jr, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:P1-04
Background: The primary aim of the NRG Oncology/NSABP B-52 clinical trial was to test if estrogen deprivation (ED) administered concomitantly with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), would improve the pCR rate in p
Autor:
Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark
Publikováno v:
Cancer Research. 83:OT2-16
Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.
Autor:
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Publikováno v:
Clinical Cancer Research. 29:1569-1581
Purpose: In KATHERINE, adjuvant T-DM1 reduced risk of disease recurrence or death by 50% compared with trastuzumab in patients with residual invasive breast cancer after neoadjuvant therapy (NAT) comprised of HER2-targeted therapy and chemotherapy. T
Autor:
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background NSABP B-42 evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease-free after 5 years of aromatase inhibitor-based (AI) therapy. Seven-year results demonstrated a non-statistically significant t